Abstract
Background Two commercial chimeric antigen receptor (CAR) T cell products, axicabtagene-ciloleucel (Yescarta (R)) and tisagenlecleucel (Kymriah (R)), are registered for the treatment of B cell neoplasia, for which an increased supply of CAR T cell products is required. Problem The production of patient-specific CAR T cells as advanced therapy medicinal products (ATMPs) poses considerable ...
Owner only: item control page
Altmetric